Respiratory disorders, which influence parts of the body’s respiratory system (for example, the lungs and the airway path) is a wide range of interminable disorders with a collection of fundamental causes, going from acquired changes to pathological inflammation. The respiratory disorders treatment market is ruled by long-acting beta agonist (LABA) and long-acting muscarinic antagonist (LAMA) treatments for chronic obstructive pulmonary disease (COPD) and asthma. These medications invigorate the muscles around the bronchial tubes to unwind and open the airway.

The increasing prevalence of COPD, asthma, and other respiratory conditions is a key driver for the global respiratory disorders treatment market. Asthma has become the most common respiratory disorder, due to increase in the prevalence of this disease among general public. This is a major factor responsible for growth of the market. Conditions such as COPD and asthma are related to rising pollution levels, changing environmental conditions, and the large population of tobacco users and smokers. As per the World Health Organization, COPD caused three million deaths globally in 2015, which accounted for 5% of total deaths across the world in the year. Moreover, indications involved in the respiratory disorders therapy area include asthma, COPD, idiopathic pulmonary fibrosis, and cystic fibrosis. There is a wide range of options available for treating these diseases. Small-molecule therapies are widely used in the treatment. It can be noted that different treatment options are available depending on the targets and the mechanism of action. However, the treatment is more focused on symptoms rather than underlying causes. Also, the treatment is evolving continuously, due to shift in interest toward innovative and targeted therapies.

The global respiratory disorders treatment market has been segmented based on respiratory drugs class and indication. Based on type of drug class, it has been segmented into anti-infectious agents (such as antibiotics and sulfas), anti-parasiticides, bronchodilators, corticosteroids, non-steroidal anti-inflammatories, and mucolytics. Among these, the bronchodilators segment holds a leading market share, owing to popularity and easy availability of these drugs and immediate response that they offer. Based on indication, the market has been divided into asthma, COPD, allergic rhinitis, pulmonary hypertension, cystic fibrosis, and idiopathic pulmonary fibrosis. Among these, the asthma segment holds the leading market share, owing to increase in the number of patients suffering from the disease and increase in awareness about its treatment.

Geographically, the respiratory disorders treatment market has been segregated into five regions viz. North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global market, owing to high incidence of respiratory disorders among people in the region. Europe is the second-largest market for respiratory disorders treatment, due to advancements in health care technologies in the region. In addition, Asia Pacific is the most emerging market for respiratory disorders treatment, due to increase in population following urban lifestyle.

Key players operating in the global respiratory disorders treatment market are AstraZeneca, Boehringer, GSK, Merck, Roche, Perrigo, Pfizer, Promedior, Prometheus, Ranbaxy, Sanofi, Shionogi, Vertex, and Novartis.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

The study is a source of reliable data on:

  • Market segments and sub-segments
  • Market trends and dynamics
  • Supply and demand
  • Market size
  • Current trends/opportunities/challenges
  • Competitive landscape
  • Technological breakthroughs
  • Value chain and stakeholder analysis

The regional analysis covers:

  • North America (U.S. and Canada)
  • Latin America (Mexico, Brazil, Peru, Chile, and others)
  • Western Europe (Germany, U.K., France, Spain, Italy, Nordic countries, Belgium, Netherlands, and Luxembourg)
  • Eastern Europe (Poland and Russia)
  • Asia Pacific (China, India, Japan, ASEAN, Australia, and New Zealand)
  • Middle East and Africa (GCC, Southern Africa, and North Africa)

The report has been compiled through extensive primary research (through interviews, surveys, and observations of seasoned analysts) and secondary research (which entails reputable paid sources, trade journals, and industry body databases). The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industry’s value chain.

A separate analysis of prevailing trends in the parent market, macro- and micro-economic indicators, and regulations and mandates is included under the purview of the study. By doing so, the report projects the attractiveness of each major segment over the forecast period.

Highlights of the report:

  • A complete backdrop analysis, which includes an assessment of the parent market
  • Important changes in market dynamics
  • Market segmentation up to the second or third level
  • Historical, current, and projected size of the market from the standpoint of both value and volume
  • Reporting and evaluation of recent industry developments
  • Market shares and strategies of key players
  • Emerging niche segments and regional markets
  • An objective assessment of the trajectory of the market
  • Recommendations to companies for strengthening their foothold in the market   

Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.

.